Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Current Assets (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Current Assets for 4 consecutive years, with $120.8 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 37.76% to $120.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.8 million through Dec 2025, down 37.76% year-over-year, with the annual reading at $120.8 million for FY2025, 37.76% down from the prior year.
  • Current Assets for Q4 2025 was $120.8 million at Century Therapeutics, down from $137.7 million in the prior quarter.
  • The five-year high for Current Assets was $383.8 million in Q2 2022, with the low at $120.8 million in Q4 2025.
  • Average Current Assets over 4 years is $224.4 million, with a median of $196.9 million recorded in 2024.
  • The sharpest move saw Current Assets plummeted 57.98% in 2023, then increased 26.16% in 2024.
  • Over 4 years, Current Assets stood at $319.7 million in 2022, then tumbled by 44.64% to $177.0 million in 2023, then rose by 9.64% to $194.1 million in 2024, then plummeted by 37.76% to $120.8 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $120.8 million, $137.7 million, and $160.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.